Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00328198
Status:
COMPLETED
Last Update Posted:
2014-03-13
First Post:
2006-05-18
Brief Title:
Subcutaneous Alemtuzumab CAMPATH MabCampath in RelapsedRefractory B-Cell Chronic Lymphocytic Leukemia
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-05
Start Date Type:
None
Primary Completion Date:
2011-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-08
Completion Date Type:
ACTUAL
First Submit Date:
2006-05-18
First Submit QC Date:
May 18 2006
Study First Post Date:
2006-05-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2012-08-10
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-02-10
Last Update Post Date:
2014-03-13
Last Update Post Date Type:
ESTIMATED